USPTO serial 85180948
ENTUITY
Reviewed by CopyMark Law Group
Status 605
- Filing date
- Status date
- Registration date
- —
- Examiner
- MCBRIDE, THEODORE M
- Law office
- OFFICE OF TRADEMARK PROGRAM CONTROL
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ENTUITY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Robert E. Lee, Jr.
ROBERT E. LEE, JR. ELI LILLY AND COMPANYLILLY CORPORATE CTRINDIANAPOLIS, IN 46285UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, anxiety, bone and skeletal diseases and disorders, blood disorders, cancer, cardiovascular diseases, cholesterol disorders, central nervous system diseases and disorders, diabetes, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, liver diseases and disorders, kidney diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, reproductive system diseases and disorders, urological disorders, dyslipidemia, sleep disorders, migraines, metabolic diseases and disorders, antipsychotics, antidepressants, anxiety spectrum disorders, atherosclerosis, Alzheimer's; pharmaceutical preparations for use in the treatment of diabetes; pharmaceutical preparations for use in the treatment of rheumatoid arthritis; pharmaceutical preparations for use in the treatment of Crohn's disease, systemic lupus erythematosus, and ankylosing spondylitis disease; pharmaceutical preparations for use in the treatment of psoriasis and psoriatic arthritis; pharmaceutical preparations for use in the treatment of autoimmune disorders | ABANDONED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 8, 2011 | MAB5 | ABANDONMENT NOTICE MAILED - AFTER PUBLICATION | — |
| Apr 8, 2011 | ABN5 | ABANDONMENT - AFTER PUBLICATION | — |
| Mar 30, 2011 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| Mar 23, 2011 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Feb 22, 2011 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 22, 2011 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 15, 2011 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jan 14, 2011 | ALIE | ASSIGNED TO LIE | — |
| Dec 21, 2010 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 21, 2010 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 23, 2010 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 23, 2010 | NWAP | NEW APPLICATION ENTERED | — |